Free Trial

Cullinan Therapeutics (CGEM) Short Interest Ratio & Short Volume

Cullinan Therapeutics logo
$12.41 -0.17 (-1.35%)
(As of 09:46 AM ET)

Cullinan Therapeutics Short Interest Data

Cullinan Therapeutics (CGEM) has a short interest of 9.02 million shares, representing 23.03% of the float (the number of shares available for trading by the public). This marks a -0.44% decrease in short interest from the previous month. The short interest ratio (days to cover) is 17.1, indicating that it would take 17.1 days of the average trading volume of 651,283 shares to cover all short positions.

Current Short Interest
9,020,000 shares
Previous Short Interest
9,060,000 shares
Change Vs. Previous Month
-0.44%
Dollar Volume Sold Short
$140.26 million
Short Interest Ratio
17.1 Days to Cover
Last Record Date
October 31, 2024
Outstanding Shares
58,230,000 shares
Float Size
39,160,000 shares
Short Percent of Float
23.03%
Today's Trading Volume
21,811 shares
Average Trading Volume
651,283 shares
Today's Volume Vs. Average
3%
Short Selling Cullinan Therapeutics?
cover of A Guide to High-Short-Interest Stocks and How to Trade Them ebook

Sign up to receive the latest short interest report for Cullinan Therapeutics and its competitors with MarketBeat's FREE newsletter.

Skip Charts & View Short Interest History

CGEM Short Interest Over Time

CGEM Days to Cover Over Time

CGEM Percentage of Float Shorted Over Time

Cullinan Therapeutics Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
10/31/20249,020,000 shares $140.26 million -0.4%23.0%17.1 $15.55
10/15/20249,060,000 shares $147.13 million -1.6%23.2%15.7 $16.24
9/30/20249,210,000 shares $154.18 million +9.4%23.6%14.2 $16.74
9/15/20248,420,000 shares $151.14 million +4.6%21.6%11.7 $17.95
8/31/20248,050,000 shares $157.78 million -1.4%20.9%10.2 $19.60
8/15/20248,160,000 shares $137.99 million -2.4%21.2%10.3 $16.91
7/31/20248,360,000 shares $161.77 million +6.0%20.6%10 $19.35
7/15/20247,890,000 shares $130.90 million +0.6%19.4%8 $16.59
6/30/20247,840,000 shares $136.73 million +73.5%19.3%8 $17.44
6/15/20244,520,000 shares $85.34 million +4.2%10.3%5.1 $18.88
5/31/20244,340,000 shares $101.99 million +16.0%11.0%5.5 $23.50
5/15/20243,740,000 shares $99.93 million +58.5%11.9%5 $26.72
4/30/20242,360,000 shares $63.74 million +40.5%10.2%3.3 $27.01
4/15/20241,680,000 shares $27.80 million +16.7%6.4%3.1 $16.55
3/31/20241,440,000 shares $24.54 million +53.9%5.5%3.4 $17.04
3/15/2024935,400 shares $14.90 million +34.8%3.6%2.3 $15.93
2/29/2024694,100 shares $12.82 million -11.5%2.6%1.8 $18.47
2/15/2024783,900 shares $14.45 million -46.7%2.9%2.3 $18.43
1/31/20241,470,000 shares $22.26 million +34.9%5.4%5.1 $15.14
1/15/20241,090,000 shares $11.54 million +3.8%4.0%5.2 $10.59
12/31/20231,050,000 shares $10.70 million -48.5%3.9%5.4 $10.19
12/15/20232,040,000 shares $16.81 million -3.3%7.5%11.1 $8.24
11/30/20232,110,000 shares $17.28 million -2.3%7.8%12.5 $8.19
11/15/20232,160,000 shares $19.16 million +0.5%8.0%13.3 $8.87
10/31/20232,150,000 shares $20.06 million -1.8%7.9%12.9 $9.33
10/15/20232,190,000 shares $19.27 million -0.5%8.1%12.9 $8.80
9/30/20232,200,000 shares $19.91 million +0.9%8.1%12.1 $9.05
9/15/20232,180,000 shares $21.71 million -17.7%8.0%11.5 $9.96
8/31/20232,650,000 shares $27.43 million +33.2%9.8%10.2 $10.35
8/15/20231,990,000 shares $20.32 million +2.6%7.4%6.4 $10.21
7/31/20231,940,000 shares $20.54 million -18.5%8.2%6.1 $10.59
7/15/20232,380,000 shares $27.89 million +15.5%10.1%7.6 $11.72
6/30/20232,060,000 shares $22.17 million -11.6%8.7%6.8 $10.76
6/15/20232,330,000 shares $29.59 million +2.6%9.9%7.6 $12.70
5/31/20232,270,000 shares $23.34 million +0.9%9.6%8.6 $10.28
5/15/20232,250,000 shares $22.37 million +0.5%9.5%10.7 $9.94
4/30/20232,240,000 shares $21.80 million +0.5%9.5%10.7 $9.73
4/15/20232,230,000 shares $22.34 million +0.5%9.5%9.9 $10.02
3/31/20232,220,000 shares $22.71 million +1.8%9.4%10.2 $10.23
3/15/20232,180,000 shares $24.44 million +3.8%7.7%10.5 $11.21
Blackrock’s Sending THIS Crypto Higher on Purpose (Ad)

It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…

2/28/20232,100,000 shares $23.71 million +1.5%7.0%13.3 $11.29
2/15/20232,070,000 shares $23.91 million +6.7%6.9%13.7 $11.55
1/31/20231,940,000 shares $22.58 million -9.4%6.6%13.7 $11.64
1/15/20232,140,000 shares $23.50 million -1.8%7.2%16.4 $10.98
12/30/20222,180,000 shares $23.00 million No Change7.4%17 $10.55
12/15/20222,180,000 shares $24.96 million No Change7.4%15.9 $11.45
11/30/20222,180,000 shares $27.10 million -5.6%7.4%14.8 $12.43
11/15/20222,310,000 shares $29.48 million -4.9%8.0%14.2 $12.76
10/31/20222,430,000 shares $31.93 million -0.4%8.5%15.4 $13.14
10/15/20222,440,000 shares $30.79 million -1.2%8.5%15.7 $12.62
9/30/20222,470,000 shares $31.67 million +14.4%8.6%14.2 $12.82
9/15/20222,160,000 shares $28.21 million -13.6%7.5%10.9 $13.06
8/31/20222,500,000 shares $33.70 million No Change8.8%10.5 $13.48
8/15/20222,500,000 shares $35.40 million +2.9%8.8%8.5 $14.16
7/31/20222,430,000 shares $32.83 million -17.9%9.9%4.1 $13.51
7/15/20222,960,000 shares $43.57 million -1.7%12.1%4.9 $14.72
6/30/20223,010,000 shares $38.59 million -0.7%12.3%5.2 $12.82
6/15/20223,030,000 shares $36.09 million +6.3%12.4%5.2 $11.91
5/31/20222,850,000 shares $30.47 million +4.0%11.7%5.3 $10.69
5/15/20222,740,000 shares $29.10 million +3.8%11.2%5.7 $10.62
4/30/20222,640,000 shares $25.90 million +7.8%11.2%14.4 $9.81
4/15/20222,450,000 shares $27.44 million -3.5%10.4%13.2 $11.20
3/31/20222,540,000 shares $26.59 million -7.3%11.0%13.3 $10.47
3/15/20222,740,000 shares $34.91 million +1.5%12.1%13.2 $12.74
2/28/20222,700,000 shares $38.72 million +5.9%12.0%10.3 $14.34
2/15/20222,550,000 shares $37.69 million -3.4%11.3%9.6 $14.78
1/31/20222,640,000 shares $35.59 million -13.7%12.1%9.9 $13.48
1/15/20223,060,000 shares $41.89 million -1.0%13.4%11.4 $13.69
12/31/20213,090,000 shares $47.68 million +27.2%14.3%10.7 $15.43
12/15/20212,430,000 shares $38.71 million +3.4%11.2%9.4 $15.93
11/30/20212,350,000 shares $42.30 million -0.8%10.9%9.9 $18.00
11/15/20212,370,000 shares $49.68 million -7.8%8.1%9.3 $20.96
10/29/20212,570,000 shares $57.11 million +0.8%8.9%10.3 $22.22
10/15/20212,550,000 shares $63.75 million -1.9%8.8%10.6 $25.00
9/30/20212,600,000 shares $58.68 million +42.9%9.0%11.7 $22.57
9/15/20211,820,000 shares $52.78 million -24.5%6.3%7.6 $29.00
8/31/20212,410,000 shares $68.01 million -11.1%8.4%11.7 $28.22
8/13/20212,710,000 shares $75.09 million No Change9.5%12.4 $27.71

CGEM Short Interest - Frequently Asked Questions

What is Cullinan Therapeutics' current short interest?

Short interest is the volume of Cullinan Therapeutics shares that have been sold short but have not yet been closed out or covered. As of October 31st, investors have sold 9,020,000 shares of CGEM short. 23.03% of Cullinan Therapeutics' shares are currently sold short. Learn More on Cullinan Therapeutics' current short interest.

What is a good short interest ratio for Cullinan Therapeutics?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CGEM shares currently have a short interest ratio of 17.0. Learn More on Cullinan Therapeutics's short interest ratio.

Which institutional investors are shorting Cullinan Therapeutics?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Cullinan Therapeutics: Jane Street Group LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for Cullinan Therapeutics?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 23.03% of Cullinan Therapeutics' floating shares are currently sold short.

Is Cullinan Therapeutics' short interest increasing or decreasing?

Cullinan Therapeutics saw a decline in short interest in October. As of October 31st, there was short interest totaling 9,020,000 shares, a decline of 0.4% from the previous total of 9,060,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Cullinan Therapeutics' float size?

Cullinan Therapeutics currently has issued a total of 58,230,000 shares. Some of Cullinan Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Cullinan Therapeutics currently has a public float of 39,160,000 shares.

How does Cullinan Therapeutics' short interest compare to its competitors?

23.03% of Cullinan Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Cullinan Therapeutics: MacroGenics, Inc. (9.41%), Innate Pharma S.A. (0.08%), Black Diamond Therapeutics, Inc. (11.19%), MorphoSys AG (0.09%), Vericel Co. (8.45%), Kymera Therapeutics, Inc. (14.14%), SpringWorks Therapeutics, Inc. (15.63%), Amneal Pharmaceuticals, Inc. (2.92%), ACADIA Pharmaceuticals Inc. (5.73%), Zai Lab Limited (4.68%),

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks.

What does it mean to sell short Cullinan Therapeutics stock?

Short selling CGEM is an investing strategy that aims to generate trading profit from Cullinan Therapeutics as its price is falling. CGEM shares are trading down $0.17 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Cullinan Therapeutics?

A short squeeze for Cullinan Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of CGEM, which in turn drives the price of the stock up even further.

How often is Cullinan Therapeutics' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CGEM, twice per month. The most recent reporting period available is October, 31 2024.




This page (NASDAQ:CGEM) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners